Gaush Meditech Ltd.(HK:2407)
HK$4.90-0.01 (-0.20%)
HK:2407
Gaush Meditech Ltd. financials statements
HK$4.90
At close:-0.01 (-0.20%)
Want to see HK:2407 full AI Analyst Report?
Gaush Meditech Ltd. (2407) Ratios
1 Followers
Gaush Meditech Ltd. Ratios
HK:2407's free cash flow for Q2 2026 was ¥27.39M. For the 2026 fiscal year, HK:2407's free cash flow was decreased by ¥-11.44M and operating cash flow was ¥38.83M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.40 | 2.25 | 1.56 | 2.69 | 2.47 |
| Quick Ratio | 1.63 | 1.60 | 1.19 | 2.12 | 1.93 |
| Cash Ratio | 0.98 | 0.82 | 0.69 | 1.46 | 1.38 |
| Solvency Ratio | 0.20 | 0.15 | 0.22 | -0.25 | -0.05 |
| Operating Cash Flow Ratio | 0.32 | 0.21 | 0.28 | 0.48 | 0.37 |
| Short-Term Operating Cash Flow Coverage | 1.07 | 0.63 | 0.48 | 1.78 | 1.34 |
| Net Current Asset Value | ¥ 160.41M | ¥ 172.65M | ¥ 244.10M | ¥ 94.93M | ¥ -1.97B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.22 | 0.23 | 0.28 | 1.08 |
| Debt-to-Equity Ratio | 0.30 | 0.35 | 0.40 | 0.51 | -3.99 |
| Debt-to-Capital Ratio | 0.23 | 0.26 | 0.28 | 0.34 | 1.33 |
| Long-Term Debt-to-Capital Ratio | 0.16 | 0.18 | 0.05 | 0.28 | 1.37 |
| Financial Leverage Ratio | 1.55 | 1.63 | 1.69 | 1.85 | -3.70 |
| Debt Service Coverage Ratio | 1.16 | 0.87 | 0.52 | 1.11 | 1.13 |
| Interest Coverage Ratio | 6.21 | 5.37 | 5.52 | 5.77 | 3.08 |
| Debt to Market Cap | 0.42 | 0.37 | 0.13 | 0.16 | 0.64 |
| Interest Debt Per Share | 3.63 | 3.98 | 4.83 | 8.24 | 28.23 |
| Net Debt to EBITDA | 0.33 | 0.53 | 0.12 | 0.13 | 7.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 45.87% | 46.44% | 49.18% | 49.88% | 46.95% |
| EBIT Margin | 8.16% | 13.62% | 21.22% | 18.11% | 18.74% |
| EBITDA Margin | 14.74% | 17.31% | 26.62% | 21.69% | 22.12% |
| Operating Profit Margin | 8.81% | 13.80% | 19.85% | 19.64% | 19.81% |
| Pretax Profit Margin | 8.31% | 10.87% | 17.62% | -21.94% | -10.63% |
| Net Profit Margin | 6.97% | 6.47% | 12.34% | -27.89% | -14.67% |
| Continuous Operations Profit Margin | 6.61% | 6.20% | 12.30% | -28.13% | -14.76% |
| Net Income Per EBT | 83.87% | 59.50% | 70.04% | 127.09% | 138.04% |
| EBT Per EBIT | 94.28% | 78.75% | 88.74% | -111.73% | -53.66% |
| Return on Assets (ROA) | 3.66% | 3.60% | 6.10% | -12.86% | -7.85% |
| Return on Equity (ROE) | 5.70% | 5.87% | 10.33% | -23.79% | 29.01% |
| Return on Capital Employed (ROCE) | 5.60% | 9.60% | 14.30% | 11.06% | 12.95% |
| Return on Invested Capital (ROIC) | 4.16% | 5.01% | 7.83% | 10.36% | 12.12% |
| Return on Tangible Assets | 7.16% | 6.79% | 10.76% | -22.82% | -15.36% |
| Earnings Yield | 8.96% | 6.77% | 3.59% | -7.92% | -4.75% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.43 | 4.89 | 9.43 | 7.43 | 7.55 |
| Payables Turnover | 9.14 | 10.88 | 7.89 | 9.15 | 10.13 |
| Inventory Turnover | 2.16 | 2.29 | 2.18 | 2.24 | 2.87 |
| Fixed Asset Turnover | 9.54 | 11.52 | 11.15 | 9.89 | 15.18 |
| Asset Turnover | 0.53 | 0.56 | 0.49 | 0.46 | 0.53 |
| Working Capital Turnover Ratio | 2.17 | 2.51 | 2.11 | 1.69 | 22.18 |
| Cash Conversion Cycle | 172.19 | 200.66 | 160.24 | 172.47 | 139.56 |
| Days of Sales Outstanding | 43.31 | 74.67 | 38.70 | 49.10 | 48.36 |
| Days of Inventory Outstanding | 168.83 | 159.56 | 167.79 | 163.27 | 127.25 |
| Days of Payables Outstanding | 39.95 | 33.56 | 46.26 | 39.90 | 36.05 |
| Operating Cycle | 212.14 | 234.22 | 206.49 | 212.37 | 175.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.99 | 0.73 | 1.68 | 2.42 | 1.72 |
| Free Cash Flow Per Share | 0.76 | 0.18 | 1.37 | 1.92 | 1.42 |
| Dividend Paid and CapEx Coverage Ratio | 1.98 | 0.47 | 5.46 | 4.88 | 5.86 |
| Capital Expenditure Coverage Ratio | 4.27 | 1.33 | 5.46 | 4.88 | 5.86 |
| Operating Cash Flow Coverage Ratio | 0.28 | 0.20 | 0.37 | 0.31 | 0.06 |
| Operating Cash Flow to Sales Ratio | 0.10 | 0.08 | 0.18 | 0.19 | 0.13 |
| Free Cash Flow Yield | 10.29% | 1.95% | 4.21% | 4.22% | 3.40% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 11.21 | 14.77 | 27.83 | -12.62 | -21.07 |
| Price-to-Sales (P/S) Ratio | 0.78 | 0.96 | 3.43 | 3.52 | 3.09 |
| Price-to-Book (P/B) Ratio | 0.64 | 0.87 | 2.87 | 3.00 | -6.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.72 | 51.36 | 23.73 | 23.67 | 29.40 |
| Price-to-Operating Cash Flow Ratio | 7.45 | 12.66 | 19.39 | 18.82 | 24.39 |
| Price-to-Earnings Growth (PEG) Ratio | 2.35 | -0.32 | -0.21 | -0.16 | 0.07 |
| Enterprise Value Multiple | 5.61 | 6.05 | 13.02 | 16.36 | 20.98 |
| Enterprise Value | 1.14B | 1.50B | 4.87B | 4.45B | 6.02B |
| EV to EBITDA | 5.61 | 6.05 | 13.02 | 16.36 | 20.98 |
| EV to Sales | 0.83 | 1.05 | 3.47 | 3.55 | 4.64 |
| EV to Free Cash Flow | 10.32 | 56.28 | 23.96 | 23.86 | 44.16 |
| EV to Operating Cash Flow | 7.91 | 13.88 | 19.57 | 18.97 | 36.63 |
| Tangible Book Value Per Share | 2.91 | 2.59 | 3.15 | 3.10 | -18.99 |
| Shareholders’ Equity Per Share | 11.64 | 10.66 | 11.35 | 15.16 | -6.85 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.20 | 0.43 | 0.30 | -0.28 | -0.39 |
| Revenue Per Share | 9.51 | 9.66 | 9.50 | 12.93 | 13.55 |
| Net Income Per Share | 0.66 | 0.63 | 1.17 | -3.61 | -1.99 |
| Tax Burden | 0.84 | 0.59 | 0.70 | 1.27 | 1.38 |
| Interest Burden | 1.02 | 0.80 | 0.83 | -1.21 | -0.57 |
| Research & Development to Revenue | 0.07 | 0.05 | 0.04 | 0.03 | 0.02 |
| SG&A to Revenue | 0.30 | 0.26 | 0.09 | 0.12 | 0.10 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.26 | 0.69 | 1.44 | -1.57 | -1.19 |
Currency in CNY
